Total Compensation: $ 2.35 M
Bruce L. Downey became a member of the Board of Directors in January 1993 and was elected Chairman of the Board and Chief Executive Officer of the Company in February 1994. From January 1993 to December 1999, he also served as the President of the Company. From 1981 to 1993, Mr. Downey was a partner in the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds. Mr. Downey currently serves as Chairman of the Board of the Generic Pharmaceutical Association (GPhA), the generic industry trade association. Mr. Downey also serves as the Chair of the Board of Ambassadors for the Johns Hopkins's Project RESTORE that funds research for new biological indicators of neuroimmunologic diseases, new imaging strategies, and clinical trials to support the creation of progressive treatments for transverse myelitis and multiple sclerosis.
Total Compensation: $ 877,983.00
William T. McKee joined the Company in January 1995 as Director of Finance and was appointed Treasurer in March 1995. In September 1996 he was appointed Chief Financial Officer and was later appointed a Vice President in December 1997 and a Senior Vice President in December 1998. Prior to joining the Company, Mr. McKee served as Vice President, Finance for a software development company and held management positions in the accounting firms of Deloitte & Touche LLP and Gramkow & Carnevale, CPAs.
Total Compensation: $ 866,743.00
Frederick J. Killion joined the Company in March 2002 as Vice President and General Counsel. Mr. Killion joined Barr from the law firm of Winston & Strawn, where he had served as a capital partner since 1999. Prior to joining Winston & Strawn in 1990, Mr. Killion was a partner in the law firm of Bishop, Cook, Purcell and Reynolds where he began as an associate in 1982. Bishop, Cook, Purcell and Reynolds merged with Winston & Strawn in 1990.
Total Compensation: $ —
Sigurd Kirk joined the Company in 2003 and has held positions of increasing responsibility in the accounting and finance functions within the finance department. Mr. Kirk began his career at Deloitte & Touche as an Audit Manager and, immediately prior to joining the Company, served as Senior Vice President of Finance & Operations for Bolt Inc., an Internet media company.
Total Compensation: $ —
James S. Gilmore, III was elected a director in May 2002. Mr. Gilmore has been a partner at the law firm of Kelley, Drye & Warren since 2002. He served as the 68th Governor of the Commonwealth of Virginia from 1997 to 2002. Mr. Gilmore also served as Chairman of the Republican National Committee from 2001 to 2002. From 1993 to 1997, he served as Virginia's Attorney General, and from 1987 to 1993 served as the Commonwealth's Attorney for Henrico County. He was Chairman of the former Congressional Advisory Commission on Terrorism and Weapons of Mass Destruction until February 2004.
Total Compensation: $ —
Catherine F. Higgins joined the Company as Vice President, Human Resources in 1991 and became Senior Vice President, Human Resources of the Company in September 2001. Prior to joining Barr, Ms. Higgins served as Vice President, Human Resources for Inspiration Resources Corporation.
Total Compensation: $ —
Christine A. Mundkur, Esq. joined the Company in 1993 as an Associate Counsel and has held a number of increasingly responsible positions in the Company's Quality and Regulatory departments. Prior to being promoted to the position of Chief Executive Officer, Barr Laboratories, Inc., she served as Executive Vice President, Global Quality, Safety and Regulatory Affairs, with responsibility for leading the Company's Global Quality, Safety, PK/BE and Regulatory Affairs operations.
Total Compensation: $ —
George P. Stephan was elected a director in February 1988. In April 1990, Mr. Stephan retired as Vice Chairman of Kollmorgen Corporation, a diversified, international technology company where he had served in several executive capacities for over 20 years. Mr. Stephan was also a director of Kollmorgen from 1982 until June 2000, when it was acquired by Danaher Corporation, and served as Chairman of the Board from 1991 to 1996. From 1994 to April 1999, Mr. Stephan also was a Managing Director of Stonington Group LLC, financial intermediaries and consultants. He is currently a business consultant and a director of Sartorius Sports Limited, a privately held specialty sports retailer.
Total Compensation: $ —
Harold N. Chefitz was elected a director in February 2001. Mr. Chefitz has been Chairman of Notch Hill Advisors, which advises CK Fund, since 1999, and President of Chefitz HealthCare Investments, a private investment company, since 1995. Prior to forming Notch Hill in 1999, Mr. Chefitz was a partner in Boles Knop & Co. Mr. Chefitz has also served as Managing Director and head of the Healthcare Group at Prudential Securities, and Senior Managing Director of Furman Selz. In 2004, Mr. Chefitz became a partner of Quanstar Group, LLC. Mr. Chefitz is a member of the board of Kensey Nash, a medical device company. From 1990 to 1994, Mr. Chefitz served as Chairman of the Board of Trustees at Columbia University School of Pharmaceutical Sciences. He is currently a member of the Boston University Medical School Advisory Board for Alzheimer's Disease.
Total Compensation: $ —
Michael J. Bogda joined the Company in 2000 as Vice President of Validation and Technical Services, and has held a number of increasingly responsible positions in the Company's Manufacturing and Global Product Supply groups. Prior to being promoted to the position of President and Chief Operating Officer of Barr Laboratories, Inc., Mr. Bogda served as Executive Vice President, Global Product Supply. Before joining the Company Mr. Bogda was Vice President, Operations and Facility Manager and a member of the Executive Management Committee at Copley Pharmaceuticals, Inc.
Total Compensation: $ 639,277.00
—
Total Compensation: $ —
Peter R. Seaver was elected a director in October 2001. He retired from a 31-year career with The Upjohn Company, a pharmaceutical manufacturer, in 1998. He held various executive positions with Upjohn including Vice President-Domestic Marketing, Corporate Vice President-Worldwide Pharmaceutical Marketing, and Corporate Vice President for Health Care Administration. Mr. Seaver served as a director of Duramed Pharmaceuticals, Inc. from 1998 until its merger with the Company in October 2001. He is currently a self-employed healthcare industry consultant.
Total Compensation: $ —
Richard R. Frankovic was elected a director in October 2001. He was employed by Rugby Laboratories from 1980 to 1998 where he served as President from 1984 until 1998. Prior to joining Rugby Laboratories, he was employed by Lederle Laboratories from 1965 to 1976, where he held a variety of management positions. Mr. Frankovic served as a director of Duramed Pharmaceuticals, Inc. from 1999 until its merger with the Company in October 2001. Since his retirement, Mr. Frankovic has been serving as a self-employed pharmaceutical industry consultant.
Total Compensation: $ —
Timothy P. Catlett joined the Company in February 1995 as Vice President, Sales and Marketing. In September 1997, Mr. Catlett was appointed Senior Vice President, Sales and Marketing of New BLI, a subsidiary of the Company. From 1978 through 1993, Mr. Catlett held a number of positions with the Lederle Laboratories division of American Cyanamid including Vice President, Cardiovascular Marketing.
Total Compensation: $ 9.22 M
Zeljko Covic joined the Company as President, Chief Operating Officer and President of the Management Board of PLIVA d.d., a subsidiary of the Company, as a result of the Company's acquisition of PLIVA d.d. Mr. Covic began his career at PLIVA in 1980. He was appointed Director of Food Production in 1985, and Marketing and Sales Director of Food in 1988. Mr. Covic spent two years as a Member of the Executive Council and Secretary for Economic Affairs in the Zagreb City Assembly from 1991 to 1993. He served as Chairman of PLIVA's Board of Directors from 1993 to 1995 and was appointed President of the PLIVA Management Board in 1995.
Total Compensation: $ 1.03 M
G. Frederick Wilkinson joined the Company in 2006 as President and Chief Operating Officer of Duramed Pharmaceuticals, Inc., the Company's proprietary products subsidiary. Prior to joining the Company, Mr. Wilkinson served as the President and Chief Executive Officer of Columbia Laboratories, Inc. from 2001 to 2006.
Total Compensation: $ —
Timothy B. Sawyer joined the Company in 1993 as Manager, Sales Administration and has held a number of increasingly responsible positions in the Company's Generic Sales and Marketing Department. Prior to being promoted to the position of Executive vice President, Global Generic Sales and Marketing Operations, Mr. Sawyer served as Senior Vice President of European Commercial Development. Before joining the Company Mr. Sawyer was associated with the law firm of Winston & Strawn
Total Compensation: $ —
Jane F. Greenman, Esq. joined the Company as Executive Vice President, Global Human Resources in 2007. Prior to joining Barr, Ms. Greenman served as Vice President, Compensation, Benefits and Labor Relations at Tyco International Ltd. Prior to this, she served as Vice President and Deputy General Counsel, Human Resources, at Honeywell, Inc from 1996 to 2003. Before joining Honeywell, she was a partner at the law firm Hughes, Hubbard & Reed.
